**
Bristol Myers Squibb is seeking a Vice President, Global Program Lead for Lymphoma, responsible for overseeing the development and commercialization of innovative therapies in the lymphoma space. The ideal candidate will have extensive experience in drug development, leadership, and cross-functional collaboration.
**
Job Summary
The Global Program Lead serves as the point of accountability for two first-in-class protein degraders in lymphoma with registrational ambition.
This role requires orchestrating the design and execution of a global integrated program strategy from candidate nomination through successful launch and commercialization.
Bristol Myers Squibb offers competitive benefits including health coverage, financial well-being protection, and flexible work-life balance options.
Matching Summary
Match Score: 75
**
Bristol Myers Squibb is seeking a Vice President, Global Program Lead for Lymphoma, responsible for overseeing the development and commercialization of innovative therapies in the lymphoma space. The ideal candidate will have extensive experience in drug development, leadership, and cross-functional collaboration.
**
Salary
Base: $341,360 - $413,648; Bonus/Equity: Additional incentive cash and stock opportunities available; Benefits: Health coverage, 401(k), paid time off, and wellbeing support programs
Skills & Requirements
Must-have
10 years drug development experience
Leading cross-functional matrix teams
Phase 3 clinical trial oversight
Regulatory filing (NDA/BLA) experience
Lymphoma therapeutic area expertise
Strategic integrated development planning
Nice-to-have
First-in-class protein degrader knowledge
Investor relations communication skills
KOL engagement and management
Commercialization strategy alignment
High performing team leadership
Enterprise mindset problem solving
Key Requirements
BS/BA required, advanced degree preferred
Minimum 10 years in drug development and commercialization
Proven leadership capability building high performing teams
Extensive working knowledge of end-to-end drug development process